2023-03-012024-02-292024-02-29false08396213Maxivision Eyecare Ltd2024-11-0686900iso4217:GBPxbrli:pure083962132023-03-01083962132024-02-29083962132023-03-012024-02-29083962132022-03-01083962132023-02-28083962132022-03-012023-02-2808396213bus:SmallEntities2023-03-012024-02-2908396213bus:AuditExempt-NoAccountantsReport2023-03-012024-02-2908396213bus:AbridgedAccounts2023-03-012024-02-2908396213bus:PrivateLimitedCompanyLtd2023-03-012024-02-2908396213core:WithinOneYear2024-02-2908396213core:AfterOneYear2024-02-2908396213core:WithinOneYear2023-02-2808396213core:AfterOneYear2023-02-2808396213core:ShareCapital2024-02-2908396213core:SharePremium2024-02-2908396213core:RevaluationReserve2024-02-2908396213core:OtherReservesSubtotal2024-02-2908396213core:RetainedEarningsAccumulatedLosses2024-02-2908396213core:ShareCapital2023-02-2808396213core:SharePremium2023-02-2808396213core:RevaluationReserve2023-02-2808396213core:OtherReservesSubtotal2023-02-2808396213core:RetainedEarningsAccumulatedLosses2023-02-2808396213core:LandBuildings2024-02-2908396213core:PlantMachinery2024-02-2908396213core:Vehicles2024-02-2908396213core:FurnitureFittings2024-02-2908396213core:OfficeEquipment2024-02-2908396213core:NetGoodwill2024-02-2908396213core:IntangibleAssetsOtherThanGoodwill2024-02-2908396213core:ListedExchangeTraded2024-02-2908396213core:UnlistedNon-exchangeTraded2024-02-2908396213core:LandBuildings2023-02-2808396213core:PlantMachinery2023-02-2808396213core:Vehicles2023-02-2808396213core:FurnitureFittings2023-02-2808396213core:OfficeEquipment2023-02-2808396213core:NetGoodwill2023-02-2808396213core:IntangibleAssetsOtherThanGoodwill2023-02-2808396213core:ListedExchangeTraded2023-02-2808396213core:UnlistedNon-exchangeTraded2023-02-2808396213core:LandBuildings2023-03-012024-02-2908396213core:PlantMachinery2023-03-012024-02-2908396213core:Vehicles2023-03-012024-02-2908396213core:FurnitureFittings2023-03-012024-02-2908396213core:OfficeEquipment2023-03-012024-02-2908396213core:NetGoodwill2023-03-012024-02-2908396213core:IntangibleAssetsOtherThanGoodwill2023-03-012024-02-2908396213core:ListedExchangeTraded2023-03-012024-02-2908396213core:UnlistedNon-exchangeTraded2023-03-012024-02-2908396213core:MoreThanFiveYears2023-03-012024-02-2908396213core:Non-currentFinancialInstruments2024-02-2908396213core:Non-currentFinancialInstruments2023-02-2808396213dpl:CostSales2023-03-012024-02-2908396213dpl:DistributionCosts2023-03-012024-02-2908396213core:LandBuildings2023-03-012024-02-2908396213core:PlantMachinery2023-03-012024-02-2908396213core:Vehicles2023-03-012024-02-2908396213core:FurnitureFittings2023-03-012024-02-2908396213core:OfficeEquipment2023-03-012024-02-2908396213dpl:AdministrativeExpenses2023-03-012024-02-2908396213core:NetGoodwill2023-03-012024-02-2908396213core:IntangibleAssetsOtherThanGoodwill2023-03-012024-02-2908396213dpl:GroupUndertakings2023-03-012024-02-2908396213dpl:ParticipatingInterests2023-03-012024-02-2908396213dpl:GroupUndertakingscore:ListedExchangeTraded2023-03-012024-02-2908396213core:ListedExchangeTraded2023-03-012024-02-2908396213dpl:GroupUndertakingscore:UnlistedNon-exchangeTraded2023-03-012024-02-2908396213core:UnlistedNon-exchangeTraded2023-03-012024-02-2908396213dpl:CostSales2022-03-012023-02-2808396213dpl:DistributionCosts2022-03-012023-02-2808396213core:LandBuildings2022-03-012023-02-2808396213core:PlantMachinery2022-03-012023-02-2808396213core:Vehicles2022-03-012023-02-2808396213core:FurnitureFittings2022-03-012023-02-2808396213core:OfficeEquipment2022-03-012023-02-2808396213dpl:AdministrativeExpenses2022-03-012023-02-2808396213core:NetGoodwill2022-03-012023-02-2808396213core:IntangibleAssetsOtherThanGoodwill2022-03-012023-02-2808396213dpl:GroupUndertakings2022-03-012023-02-2808396213dpl:ParticipatingInterests2022-03-012023-02-2808396213dpl:GroupUndertakingscore:ListedExchangeTraded2022-03-012023-02-2808396213core:ListedExchangeTraded2022-03-012023-02-2808396213dpl:GroupUndertakingscore:UnlistedNon-exchangeTraded2022-03-012023-02-2808396213core:UnlistedNon-exchangeTraded2022-03-012023-02-2808396213core:NetGoodwill2024-02-2908396213core:IntangibleAssetsOtherThanGoodwill2024-02-2908396213core:LandBuildings2024-02-2908396213core:PlantMachinery2024-02-2908396213core:Vehicles2024-02-2908396213core:FurnitureFittings2024-02-2908396213core:OfficeEquipment2024-02-2908396213core:AfterOneYear2024-02-2908396213core:WithinOneYear2024-02-2908396213core:ListedExchangeTraded2024-02-2908396213core:UnlistedNon-exchangeTraded2024-02-2908396213core:ShareCapital2024-02-2908396213core:SharePremium2024-02-2908396213core:RevaluationReserve2024-02-2908396213core:OtherReservesSubtotal2024-02-2908396213core:RetainedEarningsAccumulatedLosses2024-02-2908396213core:NetGoodwill2023-02-2808396213core:IntangibleAssetsOtherThanGoodwill2023-02-2808396213core:LandBuildings2023-02-2808396213core:PlantMachinery2023-02-2808396213core:Vehicles2023-02-2808396213core:FurnitureFittings2023-02-2808396213core:OfficeEquipment2023-02-2808396213core:AfterOneYear2023-02-2808396213core:WithinOneYear2023-02-2808396213core:ListedExchangeTraded2023-02-2808396213core:UnlistedNon-exchangeTraded2023-02-2808396213core:ShareCapital2023-02-2808396213core:SharePremium2023-02-2808396213core:RevaluationReserve2023-02-2808396213core:OtherReservesSubtotal2023-02-2808396213core:RetainedEarningsAccumulatedLosses2023-02-2808396213core:NetGoodwill2022-03-0108396213core:IntangibleAssetsOtherThanGoodwill2022-03-0108396213core:LandBuildings2022-03-0108396213core:PlantMachinery2022-03-0108396213core:Vehicles2022-03-0108396213core:FurnitureFittings2022-03-0108396213core:OfficeEquipment2022-03-0108396213core:AfterOneYear2022-03-0108396213core:WithinOneYear2022-03-0108396213core:ListedExchangeTraded2022-03-0108396213core:UnlistedNon-exchangeTraded2022-03-0108396213core:ShareCapital2022-03-0108396213core:SharePremium2022-03-0108396213core:RevaluationReserve2022-03-0108396213core:OtherReservesSubtotal2022-03-0108396213core:RetainedEarningsAccumulatedLosses2022-03-0108396213core:AfterOneYear2023-03-012024-02-2908396213core:WithinOneYear2023-03-012024-02-2908396213core:Non-currentFinancialInstrumentscore:CostValuation2023-03-012024-02-2908396213core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2023-03-012024-02-2908396213core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2023-03-012024-02-2908396213core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2023-03-012024-02-2908396213core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2023-03-012024-02-2908396213core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2023-03-012024-02-2908396213core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2023-03-012024-02-2908396213core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2023-03-012024-02-2908396213core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2023-03-012024-02-2908396213core:Non-currentFinancialInstrumentscore:CostValuation2024-02-2908396213core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2024-02-2908396213core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2024-02-2908396213core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2024-02-2908396213core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2024-02-2908396213core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2024-02-2908396213core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2024-02-2908396213core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2024-02-2908396213core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2024-02-2908396213core:Non-currentFinancialInstrumentscore:CostValuation2023-02-2808396213core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2023-02-2808396213core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2023-02-2808396213core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2023-02-2808396213core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2023-02-2808396213core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2023-02-2808396213core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2023-02-2808396213core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2023-02-2808396213core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2023-02-2808396213bus:Director12023-03-012024-02-2908396213bus:Director22023-03-012024-02-29083962131bus:Director12023-03-01083962131bus:Director12023-03-012024-02-29083962131bus:Director12024-02-29083962132023-03-01083962132023-03-012024-02-29083962132024-02-29

Maxivision Eyecare Ltd

Registered Number
08396213
(England and Wales)

Unaudited Financial Statements for the Year ended
29 February 2024

Maxivision Eyecare Ltd
Company Information
for the year from 1 March 2023 to 29 February 2024

Directors

K Choda
V Reddappachar

Company Secretary

V Reddappachar

Registered Address

5 School Sike
Carlisle
CA3 0FX

Registered Number

08396213 (England and Wales)
Maxivision Eyecare Ltd
Balance Sheet as at
29 February 2024

Notes

2024

2023

£

£

£

£

Fixed assets
Intangible assets310,716-
Tangible assets43,6734,438
14,3894,438
Current assets
Stocks1,7501,750
Debtors11,6923,958
Cash at bank and on hand1,6733,752
15,1159,460
Creditors amounts falling due within one year(19,707)(12,334)
Net current assets (liabilities)(4,592)(2,874)
Total assets less current liabilities9,7971,564
Creditors amounts falling due after one year(9,037)(12,423)
Provisions for liabilities(172)(202)
Net assets588(11,061)
Capital and reserves
Called up share capital11
Profit and loss account587(11,062)
Shareholders' funds588(11,061)
The financial statements were approved and authorised for issue by the Board of Directors on 6 November 2024, and are signed on its behalf by:
K Choda
Director
Registered Company No. 08396213
Maxivision Eyecare Ltd
Notes to the Financial Statements
for the year ended 29 February 2024

1.Accounting policies
Statutory information
The company is a private company limited by shares and registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.
Statement of compliance
The financial statements have been prepared in compliance with FRS 102 Section 1A as it applies to the financial statements for the period and there were no material departures from the reporting standard.
Revenue from sale of goods
Turnover from the sale of goods is recognised when the significant risks and rewards of ownership of the goods have transferred to the buyer. Turnover from the rendering of services is recognised by reference to the stage of completion of the contract. The stage of completion of a contract is measured by comparing the costs incurred for work performed to date to the total estimated contract costs.
Deferred tax
Deferred tax is recognised in respect of all timing differences between the recognition of income and expenses in the financial statements and their inclusion in tax assessments. Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits. Deferred tax is measured using the tax rates and laws that have been enacted or substantively enacted by the reporting date and that are expected to apply to the reversal of the timing difference, except for revalued land and investment property where the tax rate that applies to the sale of the asset is used. Current and deferred tax assets and liabilities are not discounted.
Intangible assets
Intangible assets are stated at cost less accumulated amortisation and accumulated impairment losses. The assets are reviewed for impairment if the above factors indicate that the carrying amount may be impaired. Amortisation is included in 'administrative expenses' in the profit and loss account.
Tangible fixed assets and depreciation
Tangible fixed assets are stated at cost or valuation less depreciation. Depreciation is provided on all tangible fixed assets as follows:

Reducing balance (%)Straight line (years)
Plant and machinery15-
Fixtures and fittings15-
Office Equipment-4
Stocks and work in progress
Inventories are valued at the lower of cost and estimated selling price (less any associated costs to enable such sales to complete).
2.Average number of employees

20242023
Average number of employees during the year22
3.Intangible assets

Total

£
Cost or valuation
Additions10,716
At 29 February 2410,716
Net book value
At 29 February 2410,716
At 28 February 23-
4.Tangible fixed assets

Total

£
Cost or valuation
At 01 March 2314,820
At 29 February 2414,820
Depreciation and impairment
At 01 March 2310,382
Charge for year765
At 29 February 2411,147
Net book value
At 29 February 243,673
At 28 February 234,438
5.Directors advances, credits and guarantees

Brought forward

Amount advanced

Amount repaid

Carried forward

££££
K Choda2,95913,621016,580
2,95913,621016,580